NYU Grossman School of Medicine said on Tuesday that an early study in human cells found that Pfizer Inc's antiviral drug candidate PF-00835231 may be at least as potent as the drug remdesivir in blocking the reproduction of the virus that causes COVID-19.
As part of a preliminary research conducted by NYU Grossman School of Medicine and Pfizer, PF-00835231 was shown to block the action of the viral enzyme 3CLpro (Mpro). This protease cuts up precursors into working proteins necessary for the reproduction of pandemic virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Under the first set of cell culture experiments, PF-00835231 was statistically more potent in blocking the replication of the pandemic virus (it took 3.3 times more remdesivir than PF-00835231 to fully suppress replication). In a second cell model (a 3D reconstruction of the human airway), the researchers found that both treatments were equally effective at blocking viral replication.
In conjunction, Pfizer has designed, manufactured and supplied PF-00835231. The study was funded by Pfizer, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Vilcek Foundation.
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
Ondine's Steriwave proven effective against deadly Mucor fungus
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
bioMérieux launches rapid PCR test for equine respiratory diseases
Ondine Biomedical joins CAN Health Network to advance Steriwave adoption in Canada
Seegene presrnts CURECA conceptual video at ESCMID Global 2025
GC Biopharma's BARYTHRAX receives Korean regulatory approval
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Ondine Biomedical's Steriwave technology reduces surgical site infections by 71% in NHS deployment
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Ireland selects Conduent to enhance infectious disease management